Cargando…

Prolonged ICU Stay in Severe and Critically-Ill COVID-19 Patients Who Received Convalescent Plasma Therapy

BACKGROUND: Convalescent plasma administration in severe and critically-ill COVID-19 patients have been proven to not provide improvement in patients' outcome, yet it is still widely used in countries with limited resources due to its high availability and safety. This study aims to investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Semedi, Bambang Pujo, Ramadhania, Nadya Noor, Tambunan, Betty Agustina, Bintoro, Siprianus Ugroseno Yudho, Soedarsono, Soedarsono, Prakoeswa, Cita Rosita Sigit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9473920/
https://www.ncbi.nlm.nih.gov/pubmed/36118915
http://dx.doi.org/10.1155/2022/1594342
_version_ 1784789602881503232
author Semedi, Bambang Pujo
Ramadhania, Nadya Noor
Tambunan, Betty Agustina
Bintoro, Siprianus Ugroseno Yudho
Soedarsono, Soedarsono
Prakoeswa, Cita Rosita Sigit
author_facet Semedi, Bambang Pujo
Ramadhania, Nadya Noor
Tambunan, Betty Agustina
Bintoro, Siprianus Ugroseno Yudho
Soedarsono, Soedarsono
Prakoeswa, Cita Rosita Sigit
author_sort Semedi, Bambang Pujo
collection PubMed
description BACKGROUND: Convalescent plasma administration in severe and critically-ill COVID-19 patients have been proven to not provide improvement in patients' outcome, yet it is still widely used in countries with limited resources due to its high availability and safety. This study aims to investigate its effects on ICU mortality, ICU length of stay (LoS), and improvement of oxygen support requirements. METHODS: Data of all severe and critically-ill patients in our COVID-19 ICU was collected retrospectively between May and November 2020. We dichotomized the variables and compared outcome data of 48 patients, who received convalescent plasma to 131 patients, receiving standard of care. Data were analyzed using multiple logistic regression to make prediction models of mortality, length of stay, and oxygen support device requirement. RESULT: Overall mortality rate in our COVID-19 ICU was 55.3%, with a median overall length of stay of 8 (4–11) days. Less patients that received convalescent plasma presented with the need for mechanical ventilation on ICU admission (p < 0.001), but with comparable PaO(2) to FiO(2) (P/F) ratio (p=0.95). Factors that confounded mortality were obesity (aOR = 14.1; 95% CI (1.25, 166.7); p=0.032), mechanical ventilation (aOR = 333; 95% CI (4.5,1,000); p < 0.001), higher neutrophil-to-lymphocyte ratio (NLR) (aOR = 7.32; 95% CI (1.82, 29.4); p=0.005), and lower P/F ratio (aOR = 7.70; 95% CI (2.04, 29.4); p=0.003). ICU LoS was longer in patients, who had prior history of hypertension (aOR = 2.14; 95% CI (1.05, 4.35); p=0.036) and received convalescent plasma (aOR = 3.88; 95% CI (1.77, 8.05); p < 0.001). Deceased patients, who received convalescent plasma, stayed longer in the ICU with a mean length of stay of 12.87 ± 5.7 days versus 8.13 ± 4.8 days with a significant difference (U = 434; p < 0.000). The chance of improved oxygen support requirements was lower in obese patients (aOR = 9.18; 95%CI (2.0, 42.1); p < 0.004), mechanically ventilated patients (aOR = 13.15; 95% CI (3.75, 46.09); p < 0.001), patients with higher NLR (aOR = 2.5; 95% CI (1.07, 5.85); p=0.034), and lower P/F ratio (aOR = 2.76; 95% CI (1.1, 6.91); p=0.031). CONCLUSION: The length of stay of patients in the convalescent plasma group was significantly longer than the control group. There was no effect of convalescent plasma in ICU mortality and no improvement was observed in terms of oxygen support requirements.
format Online
Article
Text
id pubmed-9473920
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-94739202022-09-15 Prolonged ICU Stay in Severe and Critically-Ill COVID-19 Patients Who Received Convalescent Plasma Therapy Semedi, Bambang Pujo Ramadhania, Nadya Noor Tambunan, Betty Agustina Bintoro, Siprianus Ugroseno Yudho Soedarsono, Soedarsono Prakoeswa, Cita Rosita Sigit Crit Care Res Pract Research Article BACKGROUND: Convalescent plasma administration in severe and critically-ill COVID-19 patients have been proven to not provide improvement in patients' outcome, yet it is still widely used in countries with limited resources due to its high availability and safety. This study aims to investigate its effects on ICU mortality, ICU length of stay (LoS), and improvement of oxygen support requirements. METHODS: Data of all severe and critically-ill patients in our COVID-19 ICU was collected retrospectively between May and November 2020. We dichotomized the variables and compared outcome data of 48 patients, who received convalescent plasma to 131 patients, receiving standard of care. Data were analyzed using multiple logistic regression to make prediction models of mortality, length of stay, and oxygen support device requirement. RESULT: Overall mortality rate in our COVID-19 ICU was 55.3%, with a median overall length of stay of 8 (4–11) days. Less patients that received convalescent plasma presented with the need for mechanical ventilation on ICU admission (p < 0.001), but with comparable PaO(2) to FiO(2) (P/F) ratio (p=0.95). Factors that confounded mortality were obesity (aOR = 14.1; 95% CI (1.25, 166.7); p=0.032), mechanical ventilation (aOR = 333; 95% CI (4.5,1,000); p < 0.001), higher neutrophil-to-lymphocyte ratio (NLR) (aOR = 7.32; 95% CI (1.82, 29.4); p=0.005), and lower P/F ratio (aOR = 7.70; 95% CI (2.04, 29.4); p=0.003). ICU LoS was longer in patients, who had prior history of hypertension (aOR = 2.14; 95% CI (1.05, 4.35); p=0.036) and received convalescent plasma (aOR = 3.88; 95% CI (1.77, 8.05); p < 0.001). Deceased patients, who received convalescent plasma, stayed longer in the ICU with a mean length of stay of 12.87 ± 5.7 days versus 8.13 ± 4.8 days with a significant difference (U = 434; p < 0.000). The chance of improved oxygen support requirements was lower in obese patients (aOR = 9.18; 95%CI (2.0, 42.1); p < 0.004), mechanically ventilated patients (aOR = 13.15; 95% CI (3.75, 46.09); p < 0.001), patients with higher NLR (aOR = 2.5; 95% CI (1.07, 5.85); p=0.034), and lower P/F ratio (aOR = 2.76; 95% CI (1.1, 6.91); p=0.031). CONCLUSION: The length of stay of patients in the convalescent plasma group was significantly longer than the control group. There was no effect of convalescent plasma in ICU mortality and no improvement was observed in terms of oxygen support requirements. Hindawi 2022-09-07 /pmc/articles/PMC9473920/ /pubmed/36118915 http://dx.doi.org/10.1155/2022/1594342 Text en Copyright © 2022 Bambang Pujo Semedi et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Semedi, Bambang Pujo
Ramadhania, Nadya Noor
Tambunan, Betty Agustina
Bintoro, Siprianus Ugroseno Yudho
Soedarsono, Soedarsono
Prakoeswa, Cita Rosita Sigit
Prolonged ICU Stay in Severe and Critically-Ill COVID-19 Patients Who Received Convalescent Plasma Therapy
title Prolonged ICU Stay in Severe and Critically-Ill COVID-19 Patients Who Received Convalescent Plasma Therapy
title_full Prolonged ICU Stay in Severe and Critically-Ill COVID-19 Patients Who Received Convalescent Plasma Therapy
title_fullStr Prolonged ICU Stay in Severe and Critically-Ill COVID-19 Patients Who Received Convalescent Plasma Therapy
title_full_unstemmed Prolonged ICU Stay in Severe and Critically-Ill COVID-19 Patients Who Received Convalescent Plasma Therapy
title_short Prolonged ICU Stay in Severe and Critically-Ill COVID-19 Patients Who Received Convalescent Plasma Therapy
title_sort prolonged icu stay in severe and critically-ill covid-19 patients who received convalescent plasma therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9473920/
https://www.ncbi.nlm.nih.gov/pubmed/36118915
http://dx.doi.org/10.1155/2022/1594342
work_keys_str_mv AT semedibambangpujo prolongedicustayinsevereandcriticallyillcovid19patientswhoreceivedconvalescentplasmatherapy
AT ramadhanianadyanoor prolongedicustayinsevereandcriticallyillcovid19patientswhoreceivedconvalescentplasmatherapy
AT tambunanbettyagustina prolongedicustayinsevereandcriticallyillcovid19patientswhoreceivedconvalescentplasmatherapy
AT bintorosiprianusugrosenoyudho prolongedicustayinsevereandcriticallyillcovid19patientswhoreceivedconvalescentplasmatherapy
AT soedarsonosoedarsono prolongedicustayinsevereandcriticallyillcovid19patientswhoreceivedconvalescentplasmatherapy
AT prakoeswacitarositasigit prolongedicustayinsevereandcriticallyillcovid19patientswhoreceivedconvalescentplasmatherapy